Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Connetics Corp.

Division of GlaxoSmithKline PLC
www.connetics.com

Latest From Connetics Corp.

Rigel Downsizes R&D To Ready Fostamatinib Commercial Effort

Biotech will cut 46 staff, mostly in research, including the entire antibody group, to focus on commercializing its Phase III thrombocytopenia candidate fostamatinib. Rigel adds industry vet Eldon Mayer to head up commercial team.

Immune Disorders Business Strategies

Investors Set Their Sights On Horizon Pharma

Horizon Pharma has emerged out of two transformative deals as a high-growth specialty pharma with four commercially available drugs. Now it is on track to achieve profitability in 2014, and investors are perking up to hear more about the company’s acquisitive strategy, which includes more aggressive dealmaking.

BioPharmaceutical

Horizon Pharma Bets On The Luck Of The Irish With Vidara Buyout

The specialty pharma agreed to buy Ireland-based Vidara Therapeutics in a cash-and-stock transaction valued at $660 million. Horizon will gain a new commercial product, Actimmune, to add to its portfolio.

BioPharmaceutical United States

Medical Dermatology Gets Under VCs' Skin

In the pharmaceutical industry, dermatology is the new ophthalmology. Like ophtho, dermatology has long been viewed as a pharmaceutical backwater dogged by a diverse set of problems, including a fragmented market, drug delivery challenges, and less than effective therapies. Today's market forces, however, are driving Big Pharma into a more specialized direction, and in the past three years, many - if not all - Big Pharmas have reoriented their pipelines, refocusing on areas of high unmet medical need in the hopes of identifying novel drugs that have a greater chance of passing muster with regulators and succeeding in the marketplace. Freed from the need to pursue blockbuster products, dermatology assets are suddenly more attractive.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Therapeutic Areas
  • Dermatology
  • Infectious & Viral Diseases
  • Alias(es)
  • Connective Therapeutics
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Tom Carey, VP, Commercial Oper.
    James A Trah, VP, Mktg.
    David B Hirsch, VP, Sales
    Greg Vontz, Pres. & COO
  • Contact Info
  • Connetics Corp.
    Phone: (650) 843-2800
    3290 W. Bayshore Rd.
    Palo Alto, CA 94303
    USA
UsernamePublicRestriction

Register